C-Reactive protein velocity and the risk of new onset atrial fibrillation among st elevation myocardial infarction patients

David Zahler, Llan Merdler, Keren Lee Rozenfeld, Gil Shenberg, Assi Milwidsky, Shlomo Berliner, Shmuel Banai, Yaron Arbel, Yacov Shacham

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Background: Elevated C-reactive protein (CRP) was shown to be associated with an increased risk for new-onset atrial fibrillation (AF) in ST elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary interven tion (PCI); however, the optimal time frame to measure CRP for risk stratification is not known. Objectives: To evaluate the relation between the change in CRP over time (CRP velocity [CRPv]) and new-onset AF among STEMI patients treated with primary PCI. Methods: We included 801 STEMI patients who underwent PCI between 2007 and 2017 and had their CRP measured with a wide range assay (wr-CRP) at least twice during the 24 hours after admission. CRPv was defined as the change in wr-CRP concentration (mg/l) divided by the change in time (in hours] between the two measurements. Patient medical records were reviewed for occurrence of new-onset AF. Results: New onset AF occurred in 45 patients (6%). Patients with new onset AF had significantly higher median CRPv (1.27 vs. 0.43 mg/l/h, P = 0.002). New-onset AF during hospitaliza tion occurred in 3.4%, 4.5 %, and 9.1% of patients in the first, second and third CRPv tertiles, respectively (P for trend = 0.006). In a multivariable logistic regression, adjusting for clin ical variables the odds ratios for new onset AF was 1.93 (95% confidence interval 1.0-3.59, P= 0.04) for patients in the third CRPv tertile. Conclusion: CRPv might be an independent and rapidly mea surable biomarker for new-onset AF following primary PCI in STEMI patients.

Original languageEnglish
Pages (from-to)169-173
Number of pages5
JournalIsrael Medical Association Journal
StatePublished - Mar 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 Israel Medical Association. All rights reserved.


  • Acute myocardial infarction
  • Atrial fibrillation (AF)
  • Biomarkers
  • C-reactive protein (crp)
  • Primary percutaneous coronary in tervention (pci)


Dive into the research topics of 'C-Reactive protein velocity and the risk of new onset atrial fibrillation among st elevation myocardial infarction patients'. Together they form a unique fingerprint.

Cite this